Why the study?
Does type 2 diabetes reduce the effectiveness of intravenous thrombolysis and worsen long-term prognosis in patients with ST elevation myocardial infarction?
Population
726 consecutive subjects with ST elevation myocardial infarction who received intravenous thrombolysis in…
Comparison
Type 2 diabetes (exposure) vs Nondiabetic subjects
Design
Cohort
Follow-up
3.5 years
Authors
Loading...
Diabetes may impair ST recovery after thrombolysis in STEMI; hypothesis-generating for diabetes-specific reperfusion strategies.
Does type 2 diabetes reduce the effectiveness of intravenous thrombolysis and worsen long-term prognosis in patients with ST elevation myocardial infarction?
Type 2 diabetes is a strong predictor of acute intravenous thrombolysis failure and is associated with worse long-term prognosis in patients with STEMI.
Zairis et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: